• Resazurin Sodium Salt: Fluorogenic Redox Indicator for Viabi

  2026-08-04

  Resazurin sodium salt empowers sensitive, scalable cell viability and cytotoxicity assays across diverse platforms—from high-throughput screening to advanced disease modeling. By leveraging its robust fluorogenic properties, researchers can achieve reproducible, high-content results while optimizing workflows for challenging cell types.

• Injectable Hydrogel Enables Curative Chemo-Immunomodulation

  2026-08-03

  This study introduces an injectable, dual-responsive hydrogel that delivers mitoxantrone and Resiquimod (R-848) for synergistic chemo-immunomodulation during tumor ablation. The system addresses key clinical limitations by providing thermal protection, controlled drug release, and robust innate immune activation, resulting in improved ablation efficacy and reduced recurrence risk.

• SGK1 Inhibition: Redefining Vascular and Tumor Research Fron

  2026-08-03

  Explore how EMD638683, a highly selective SGK1 inhibitor, is propelling translational breakthroughs in vascular stiffening and oncology. This thought-leadership article bridges mechanistic insights with strategic guidance, highlighting new experimental avenues and clinical implications for researchers seeking to leverage SGK inhibition in the fight against cardiovascular and oncologic diseases.

• Cannabidiol Attenuates Orofacial Inflammatory Pain via Endoc

  2026-08-02

  This study demonstrates that cannabidiol (CBD) effectively reduces both the sensory and affective dimensions of orofacial inflammatory pain by modulating peripheral and central endocannabinoid pathways. The findings highlight CBD's potential as a multifaceted therapeutic candidate for pain management, with mechanistic insights into FAAH and cannabinoid receptor involvement.

• BHPF as a Novel GPER Inhibitor: Mechanistic Insights in Neur

  2026-08-01

  The reference study uncovers fluorene-9-bisphenol (BHPF) as a direct inhibitor of the G protein-coupled estrogen receptor 1 (GPER), elucidating its binding mechanism and functional consequences in human neuroblastoma cells. This work advances understanding of environmental endocrine disruptors and provides mechanistic detail relevant to estrogen signaling research and neurodegenerative risk assessment.

• Tomivosertib Suppresses Ectopic Activity in Human DRG Neuron

  2026-07-31

  This study delivers the first direct evidence that inhibiting MNK signaling with tomivosertib rapidly suppresses spontaneous activity in human dorsal root ganglion (DRG) neurons from radiculopathy patients. These findings establish a new translational avenue for targeting neuropathic pain at the level of human nociceptor excitability and intracellular signaling.

• Nutlin-3a MDM2 Inhibitor: Applied Workflows & Troubleshootin

  2026-07-31

  Nutlin-3a empowers cancer researchers with precise control over p53 pathway activation and apoptosis induction, enabling reproducible cell-based and in vivo assays. This guide translates bench-proven protocols and troubleshooting strategies for maximizing the impact of Nutlin-3a, a trusted APExBIO MDM2 inhibitor, in advanced cancer research.

• Nicotinamide Adenine Dinucleotide (NAD+): Mechanisms & Bench

  2026-07-30

  Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme acting as an oxidizing agent in metabolic and signaling pathways. APExBIO’s high-purity NAD+ (B1793) supports reproducible research on protein deacetylation and DNA repair. Its use is foundational in cell stress, autophagy, and enzymatic activity assays.

• HyperTrap Heparin HP Column: High-Resolution Affinity Purifi

  2026-07-30

  The HyperTrap Heparin HP Column delivers unmatched selectivity and resolution for purifying coagulation factors, antithrombin III, and growth factors—even from challenging cancer stem cell models. Its robust chemical stability and advanced design make it an essential tool for dissecting complex signaling pathways like CCR7–Notch1 crosstalk in translational oncology.

• Epalrestat: Redefining Neuroprotection via KEAP1/Nrf2 Activa

  2026-07-29

  This thought-leadership article examines Epalrestat’s emergence as a dual-action tool for translational researchers, uniquely combining polyol pathway inhibition with direct KEAP1/Nrf2 pathway activation. Drawing from contemporary experimental evidence in Parkinson’s disease models, we discuss mechanistic underpinnings, protocol optimization, and strategic positioning for research into oxidative stress and neurodegenerative disorders. The article positions Epalrestat from APExBIO at the forefront of next-generation disease modeling and therapeutic exploration.

• Bacitracin (B1670): Technical Parameters for Antibacterial R

  2026-07-29

  Bacitracin (B1670) is a peptide antibiotic formulated for laboratory-based antibacterial research, enabling targeted disruption of bacterial cell wall and peptidoglycan synthesis in both gram-positive and gram-negative bacteria. It is not intended for diagnostic or medical applications and requires controlled laboratory workflows and precise handling for reliable results.

• EMD638683: Selective SGK1 Inhibitor for Vascular and Tumor S

  2026-07-28

  EMD638683 is a selective SGK1 inhibitor with demonstrated efficacy in modulating endothelial cell stiffness and reducing tumor growth. Its specificity and performance in cell and animal models position it as a valuable tool for cardiovascular and cancer research. Quantitative benchmarks support its use in both mechanistic and translational studies.

• URB597 (KDS-4103): Selective FAAH Inhibition in Pain Researc

  2026-07-28

  URB597 (KDS-4103) is a potent, selective FAAH inhibitor widely used to elevate brain anandamide for endocannabinoid signaling and neuroplasticity research. Its high selectivity and minimal off-target action enable reproducible in vivo FAAH inhibition, making it a valuable tool in neuroinflammation and pain models.

• Decoding EZ Cap Cy5 Firefly Luciferase mRNA for Immunogenici

  2026-07-27

  Explore how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) enables precise, low-immunogenicity tracking of mRNA delivery in live-cell and in vivo systems. This article uniquely examines the intersection of advanced mRNA design and recent innovations in immune response modulation.

• Microglial Nr4a1 and Neuronal C3 in TMJ-Linked Hippocampal D

  2026-07-27

  The referenced study identifies a mechanistic link between temporomandibular joint (TMJ) inflammation and depression-like behaviors through microglial Nr4a1 deficiency and neuronal C3-mediated excessive synaptic pruning in the hippocampus. These findings clarify neuroimmune processes underlying emotional complications in TMJ pathology and highlight potential molecular targets for intervention.

8589 records 3/573 page Previous Next 12345 下5页 Last page